Medison, uniQure N.V. deal

uniQure granted Medison exclusive rights to commercialize Glybera alipogene tiparvovec in Israel and Palestine to treat lipoprotein lipase (LPL) deficiency. Medison will be responsible for regulatory filings in the territories. The partners are not disclosing financial terms. Glybera is an adeno-associated virus (AAV) vector encoding the LPL gene given as a single intramuscular injection. ...